Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO

Novo Nordisk other non-current liabilities for the quarter ending September 30, 2024 were $1.129B, a 26.05% increase year-over-year.

  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
  • Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.
  • Novo Nordisk other non-current liabilities for 2021 were $0.753B, a 8.62% increase from 2020.

Novo Nordisk Other Non-Current Liabilities 2010-2024 | NVO

  • Novo Nordisk other non-current liabilities for 2023 were $0.993B, a 49.51% increase from 2022.
  • Novo Nordisk other non-current liabilities for 2022 were $0.664B, a 11.83% decline from 2021.
  • Novo Nordisk other non-current liabilities for 2021 were $0.753B, a 8.62% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$789.4B
Johnson & Johnson (JNJ)$374.3B
AbbVie (ABBV)$352.5B
Merck (MRK)$260.4B
Novartis AG (NVS)$217.6B
AstraZeneca (AZN)$200B
Pfizer (PFE)$151.4B
Sanofi (SNY)$130.2B
Innoviva (INVA)$1.3B